Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Pasatru / Garetosmab for Fibrodysplasia Ossificans Progressiva

As of October 2026, MARA’s assessment finds Pasatru / Garetosmab’s reimbursement risk concentrated in quality of life, with care pathway integration a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs safety and adverse effects: what harms arrive alongside the benefit, which payers set against the gains before funding a treatment. The strength recorded in care pathway integration carries weight because that domain asks how the drug fits into the way care is organised today; a treatment that demands new infrastructure or displaces an established pathway faces extra scrutiny.

Rare Diseases

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

The OPTIMA trial showed a significant reduction in new CT-detected HO lesions with garetosmab compared to placebo, with rate ratios of 0.06 and 0.10. However, the trial had a small sample size and wide confidence intervals, limiting the certainty of the magnitude of effect.

Does the economic case hold at the expected price? — Cost effectiveness

No cost-utility analysis, ICER, or economic model was identified for garetosmab, making cost-effectiveness not assessable.

Is there quality-of-life evidence payers weigh? — Quality of life

While several HRQoL instruments were used, no significant patient-reported flare-up differences were found, and no utility or functional results were publicly available, limiting the assessment of HRQoL benefits.

Does the safety profile hold up for payers? — Safety and Adverse Effects

OPTIMA reported common adverse events such as abscesses and acne, with no deaths through week 56. However, long-term safety remains uncertain due to the small exposed population and potential risks like embryo-fetal toxicity.

Was the drug compared against what payers expect? — Comparator Selection

Placebo was an acceptable comparator at trial initiation, but the relevance has decreased with the availability of other treatments like palovarotene. No direct comparison with active treatments was made.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trial population was representative of young adults with classic FOP, but lacked diversity and did not include children or older adults, limiting generalizability.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

The treatment fits into existing pathways with minor adjustments needed for infusion administration and monitoring, which are manageable within current healthcare settings.

Are the wider system costs understood? — Resource Use and Cost Implications

No budget-impact or resource-use data were presented, making it not assessable.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The OPTIMA trial was a well-designed phase 3 RCT with high retention and prespecified endpoints, but had limitations in sample size and lack of active control.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

High uncertainty remains due to small lesion counts, wide confidence intervals, and lack of long-term functional outcomes. The direction of effect is consistent, but magnitude and clinical translation are uncertain.

Be alerted when this rating changes:

Sample two-page MARA Rating report for the fictional drug Samplinib: page one with the rating, its key numbers and the past decisions on drugs in the same rating band; page two with the ten graded payer-side domains and the reasoning behind each
Every MARA rating is delivered as a two-page reasoned report (sample, fictional product) — see it in full
Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.